Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy

Prognostic studies of insulin-like growth factor-1 receptor(IGF-1R) inhibitors in cancer therapy had promising results in infratests, which exhibited that IGF-1R signalling was crucial in cancer cells growth. However, the conclusion of later clinical trials revealed a dim future for IGF-1R inhibitor...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncotarget 2017-04, Vol.8 (17), p.29501-29518
Hauptverfasser:	Qu, Xiao, Wu, Zhinan, Dong, Wei, Zhang, Tiehong, Wang, Liguang, Pang, Zhaofei, Ma, Wei, Du, Jiajun
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Humans Middle Aged Neoplasms - drug therapy Neoplasms - mortality Neoplasms - pathology Prognosis Receptor, IGF Type 1 - antagonists & inhibitors Review Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!